Hasil Pencarian - David Fitchett

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Clinical trial update: focus on the ONTARGET study

    Clinical trial update: focus on the ONTARGET study oleh David Fitchett

    Diterbitkan 2008-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

    Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME oleh Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann, JoAnn Lindenfeld

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

    Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial oleh David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

    Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial oleh João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio E. Inzucchi

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome

    Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome oleh Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease

    Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease oleh Abhinav Sharma, Silvio E. Inzucchi, Jeffrey M. Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus, Subodh Verma, Faiez Zannad, Christoph Wanner, Bettina J. Kraus

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

    Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial oleh Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial

    Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial oleh Ayodele Odutayo, MD, DPhil, Bernard Zinman, MD, Christoph Wanner, MD, Isabella Zwiener, PhD, Søren S. Lund, MD, Stefan Hantel, PhD, David Fitchett, MD, Jacob A. Udell, MD

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

    Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial oleh David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: